CoChat

Preclinical Safety Evaluation of a Recombinant AAV8 Vector for X-Linked Retinoschisis After Intravitreal Administration in Rabbits

Open access
Marangoni, Dario, Wu, Zhijian, Wiley, Henry E., Zeiss, Caroline J., Vijayasarathy, Camasamudram, Zeng, Yong, Hiriyanna, Suja, Bush, Ronald A., Wei, Lisa L., Colosi, Peter, Sieving, Paul A. · 2014 · Human Gene Therapy Clinical Development
Cited by 29

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

X-linked retinoschisis (XLRS) is a retinal disease caused by mutations in the gene encoding the protein retinoschisin (RS1) and one of the most common causes of macular degeneration in young men. Currently, no FDA-approved treatments are available for XLRS and a replacement gene therapy could provide a promising strategy. We have developed a novel gene therapy approach for XLRS, based on the administration of AAV8-scRS/IRBPhRS, an adeno-associated viral vector coding the human RS1 protein, via the intravitreal route. On the basis of our prior study in an Rs1-KO mouse, this construct transduces efficiently all the retinal layers, resulting in an RS1 expression similar to that observed in the wild-type and improving retinal structure and function. In support of a clinical trial, we carried out a study to evaluate the ocular safety of intravitreal administration of AAV8-scRS/IRBPhRS into 39 New Zealand White rabbits. Two dose levels of vector, 2e(10) and 2e(11) vector genomes per eye (vg/eye), were tested and ocular inflammation was monitored over a 12-week period by serial ophthalmological and histopathological analysis. A mild ocular inflammatory reaction, consisting mainly of vitreous infiltrates, was observed within 4 weeks from injection, in both 2e(10) and 2e(11) vg/eye groups and was likely driven by the AAV8 capsid. At 12-week follow-up, ophthalmological examination revealed no clinical signs of vitreitis in either of the dose groups. However, while vitreous inflammatory infiltrate was significantly reduced in the 2e(10) vg/eye group at 12 weeks, some rabbits in the higher dose group still showed persistence of inflammatory cells, histologically. In conclusion, intravitreal administration of AAV8-scRS/IRBPhRS into the rabbit eye produces a mild and transient intraocular inflammation that resolves, at a 2e(10) vg/eye dose, within 3 months, and does not cause irreversible tissue damages. These data support the initiation of a clinical trial of intravitreal administration of AAV8-scRS/IRBPhRS in XLRS patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/humc.2014.067

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 30

  1. 10.1167/iovs.06-0145 · doi:10.1167/iovs.06-0145
  2. 10.1227/01.neu.0000279944.12903.2c · DOI
  3. 10.1016/j.preteyeres.2010.03.004 · DOI · Paper page
  4. 10.1073/pnas.0807027105 · DOI · Paper page
  5. Dalkara D., 2013, Sci. Transl. Med., 189, 189ra76
  6. 10.1001/archopht.123.11.1563 · DOI
  7. 10.1073/pnas.182412299 · DOI · Paper page
  8. 10.1001/archophthalmol.2009.398 · DOI
  9. 10.1136/bjo.79.7.697 · DOI · Paper page
  10. 10.1001/archopht.125.4.571 · DOI
  11. 10.1093/hmg/9.12.1873 · DOI · Paper page
  12. 10.1182/blood-2003-02-0495 · DOI · Paper page
  13. 10.3109/02713683.2013.779720 · DOI · Paper page
  14. 10.1097/IAE.0b013e318030c517 · DOI
  15. 10.1002/jgm.1126 · DOI · Paper page
  16. Li Q., 2008, Mol. Vis., 14, 1760
  17. 10.1007/s00417-008-0765-z · DOI
  18. 10.1016/S1474-4422(10)70254-4 · DOI · Paper page
  19. Molday L.L., 2001, Invest. Ophthalmol. Vis. Sci., 42, 16
  20. 10.1038/gt.2009.61 · DOI · Paper page
  21. Sieving P.A., 2009, GeneReviews® [Internet], 1993
  22. 10.1111/j.1365-2567.2005.02239.x · DOI · Paper page
  23. 10.1038/mt.2008.41 · DOI · Paper page
  24. 10.1093/ilar.50.2.206 · DOI · Paper page
  25. 10.1167/iovs.04-0156 · DOI · Paper page
  26. Takada Y., 2006, Mol. Vis., 12, 1108
  27. 10.1126/scitranslmed.3002103 · DOI · Paper page
  28. 10.1038/nbt1073 · DOI · Paper page
  29. 10.1074/jbc.M413117200 · DOI
  30. 10.1167/iovs.04-0576 · DOI · Paper page

Cited by

See all 29

Metadata

Authors
Marangoni, D., Wu, Z., Wiley, H. E., Zeiss, C. J., Vijayasarathy, C., Zeng, Y., Hiriyanna, S., Bush, R. A., Wei, L. L., Colosi, P., & Sieving, P. A.
Venue
Human Gene Therapy Clinical Development
Published
2014-12
Volume
25
Issue
4
Pages
202-211
ISSN
  • 2324-8637 (ISSN-L)
  • 2324-8645
OpenAlex
W2329402578
Cited by
29
References
11
FWCI
1.78
Type
journal article
Language
en
Open access
green
Licence
www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.